Payer Perceptions of Fairness in Pricing Rare Disease Therapies

Charles Rivers Associates’ Andrew Parece and Matthew Majewski discuss how payers view the pricing of rare disease therapies, how context changes perceptions around pricing, and why they began their questioning of payers around the issue of fairness.